Corthera is a biopharmaceutical company, recently acquired by Novartis Pharmaceuticals Corporation, committed to developing and commercializing therapies for the acute care setting.
Corthera's lead product candidate, relaxin, has recently completed the Phase II portion of a global Phase II/III clinical trial in acute heart failure and will be entering Phase III in early 2009. Corthera has worldwide rights to develop and commercialize relaxin and owns a broad intellectual property portfolio covering all relevant therapeutic applications of relaxin.
Relaxin is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure.
Corthera's Phase II/III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, international trial was designed to evaluate the efficacy and safety of relaxin for the treatment of AHF. Patients enrolled in the study presented to the hospital with dyspnea (breathlessness) due to AHF with elevated blood pressure and renal dysfunction. Patients were treated with a 48-hour IV infusion of relaxin or placebo. Final results of the Phase II portion of the study were completed in December 2008.